Frank Torti, MD
Vant Chair, Roivant Sciences
Frank Torti is the Vant Chair at Roivant Sciences. Dr. Torti serves as Chairman of the Board of the companies in the Roivant Pharma family and is responsible for the management of those businesses. He previously served as Vant Investment Chair, where he oversaw a group of companies responsible for the development of thirty-five investigational drugs in eleven therapeutic areas and over fifty clinical trials, including four successful Phase 3 trials. Dr. Torti joined Roivant in 2018 from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today.
Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics. Dr. Torti received his M.D. from the University of North Carolina School of Medicine and his M.B.A. with distinction from Harvard Business School.